Thornton B P, Vĕtvicka V, Pitman M, Goldman R C, Ross G D
Department of Pathology, University of Louisville, KY 40292, USA.
J Immunol. 1996 Feb 1;156(3):1235-46.
Zymosan, the cell wall from Saccharomyces cerevisiae, was reported to be a macrophage activator through its beta-glucan over 30 yr ago. Nevertheless, the identity of the beta-glucan receptor has been controversial. This study showed that the alpha M beta 2-integrin, CR3 (Mac-1, CD11b/CD18) served as the beta-glucan receptor through one or more lectin sites located outside of the CD11b I-domain that contains the binding sites for iC3b, ICAM-1, and fibrinogen. Sugar specificity, analyzed with FITC-labeled soluble polysaccharides and flow cytometry, showed CR3-specific staining with several pure beta-glucans but not with alpha-mannan. However, a 10-kDa soluble zymosan polysaccharide (SZP) with high affinity (6.7 x 10(-8) M) for CR3 consisted largely of mannose and approximately 5% glucose. Binding of either SZP-FITC or beta-glucan-FITC to CR3 was blocked not only by pure beta-glucans from yeast, mushroom, seaweed, or barley, but also by N-acetyl-D-glucosamine (NADG), alpha- or beta-methylmannoside, and alpha- or beta-methyl-glucoside. SZP-FITC and beta-glucan-FITC stained all leukocyte types similarly to anti-CR3-FITC, and polysaccharide-FITC staining was inhibited > or = 95% by unlabeled anti-CR3. SZP-FITC staining of cells expressing recombinant chimeras between CR3 and CR4 (p150,95, CD11c/CD18) suggested that both the divalent cation-binding region of CD11b and the region C-terminal to it may regulate binding of polysaccharides to CR3. Unlabeled SZP or beta-glucan also blocked CR3 staining by 11 mAb to C-terminal domain epitopes of CD11b but had no effect on staining by mAb directed to the I-domain. In conclusion, CR3 serves as the leukocyte beta-glucan receptor through a cation-independent lectin site located C-terminal to the I-domain of CD11b. Its sugar specificity is broader than originally appreciated, allowing it to react with certain polysaccharides containing mannose or NADG, as well as glucose.
酵母聚糖是酿酒酵母的细胞壁,30多年前就有报道称它通过其β-葡聚糖可激活巨噬细胞。然而,β-葡聚糖受体的身份一直存在争议。本研究表明,αMβ2整合素CR3(Mac-1,CD11b/CD18)通过位于CD11b I结构域之外的一个或多个凝集素位点充当β-葡聚糖受体,该结构域包含iC3b、ICAM-1和纤维蛋白原的结合位点。用异硫氰酸荧光素(FITC)标记的可溶性多糖和流式细胞术分析糖特异性,结果显示几种纯β-葡聚糖可使CR3特异性染色,而α-甘露聚糖则不能。然而,一种对CR3具有高亲和力(6.7×10-8 M)的10 kDa可溶性酵母聚糖多糖(SZP)主要由甘露糖和大约5%的葡萄糖组成。SZP-FITC或β-葡聚糖-FITC与CR3的结合不仅被来自酵母、蘑菇、海藻或大麦的纯β-葡聚糖阻断,还被N-乙酰-D-葡糖胺(NADG)、α-或β-甲基甘露糖苷以及α-或β-甲基葡糖苷阻断。SZP-FITC和β-葡聚糖-FITC对所有白细胞类型的染色与抗CR3-FITC相似,未标记的抗CR3可使多糖-FITC染色抑制≥95%。对表达CR3和CR4(p150,95,CD11c/CD18)之间重组嵌合体的细胞进行SZP-FITC染色,结果表明CD11b的二价阳离子结合区域及其C末端区域可能调节多糖与CR3的结合。未标记的SZP或β-葡聚糖也可阻断11种针对CD11b C末端结构域表位的单克隆抗体(mAb)对CR3的染色,但对针对I结构域的mAb染色无影响。总之,CR3通过位于CD11b I结构域C末端的一个不依赖阳离子的凝集素位点充当白细胞β-葡聚糖受体。其糖特异性比最初认为的更广泛,使其能够与某些含有甘露糖或NADG以及葡萄糖的多糖发生反应。